[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?] (Q94601377)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17870550%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

review article

1 reference

title

[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17870550%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

author name string

Jean-Pierre Valat

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17870550%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

Gilbert Deray

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17870550%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

François Héloire

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17870550%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

language of work or name

French

0 references

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17870550%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17870550%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

volume

35 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17870550%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

page(s)

25-34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17870550%20AND%20SRC:MED&resulttype=core&format=json

The coxibs, selective inhibitors of cyclooxygenase-2.

17 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Association between naproxen use and protection against acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Selective cyclooxygenase 2 inhibitors and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Relative thromboembolic risks associated with COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Non-narcotic analgesic dose and risk of incident hypertension in US women

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Relationship between COX-2 specific inhibitors and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974937-5

7 January 2021

10.1016/S0755-4982(06)74937-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17870550%20AND%20SRC:MED&resulttype=core&format=json

17 May 2020

1 reference